Therapeutic Effect of ME1036 on Endocarditis Experimentally Induced by Methicillin-Resistant Staphylococcus aureus-Reference-Cited by-同舟云学术

Therapeutic Effect of ME1036 on Endocarditis Experimentally Induced by Methicillin-Resistant Staphylococcus aureus

Published:2005-08 Issue:8 Volume:49 Page:3526-3528
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Nagura Jun¹,Kijima Koji¹,Kurazono Mizuyo¹,Takahata Sho¹,Sugano Toshie¹,Tanaka Yukari¹,Hirai Yoko¹,Yamada Keiko¹,Takayama Yoshihiro¹,Shitara Eiki¹,Yonezawa Minoru¹

Affiliation:

1. Pharmaceutical Research Department, Meiji Seika Kaisha, Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama 222-8567, Japan

Abstract

ABSTRACT The efficacy of ME1036, a novel parenteral carbapenem, was compared with that of vancomycin by using a rabbit model of methicillin-resistant Staphylococcus aureus (MRSA) endocarditis. Compared with vancomycin, ME1036 reduced the bacterial counts in the vegetations at a lower dosage or over a shorter period of administration when it was used for the treatment of MRSA endocarditis.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.49.8.3526-3528.2005

Reference11 articles.

1. Abraham, J., C. Mansour, E. Veledar, B. Khan, and S. Lerakis. 2004. Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S. aureus bacteremia. Am. Heart J.147:536-539.

2. Bonow, R. O., B. Carabello, A. C. de Leon, L. H. Edmunds, Jr., B. J. Fedderly, M. D. Freed, W. H. Gaasch, C. R. McKay, R. A. Nishimura, P. T. O'Gara, R. A. O'Rourke, S. H. Rahimtoola, J. L. Ritchie, M. D. Cheitlin, K. A. Eagle, T. J. Gardner, A. Garson, Jr., R. J. Gibbons, R. O. Russell, T. J. Ryan, and S. C. Smith, Jr. 1998. ACC/AHA guidelines for the management of patients with valvular heart disease. Executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on Management of Patients with Valvular Heart Disease). J. Heart Valve Dis.7:672-707.

3. Durack, D. T., and P. B. Beeson. 1972. Experimental bacterial endocarditis. I. Colonization of a sterile vegetation. Br. J. Exp. Pathol.53:44-49.

4. In Vitro Activities of ME1036 (CP5609), a Novel Parenteral Carbapenem, against Methicillin-Resistant Staphylococci

5. Lefort, A., and B. Fantin. 1999. Rabbit model of bacterial endocarditis, p. 611-617. In O. Zak and M. A. Sande (ed.), Handbook of animal models of infection. Academic Press, Inc., New York, N.Y.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Total Synthesis of ME1036 Starting from Readily Available Inexpensive Materials;Letters in Organic Chemistry;2015-11-02

2. β‐Lactam Antibiotics;Burger's Medicinal Chemistry and Drug Discovery;2010-09-15

3. Molecular Basis and Phenotype of Methicillin Resistance in Staphylococcus aureus and Insights into New β-Lactams That Meet the Challenge;Antimicrobial Agents and Chemotherapy;2009-10

4. Efficacy of ME1036 against meticillin-resistant Staphylococcus aureus and vancomycin-insensitive S. aureus in a model of haematogenous pulmonary infection;International Journal of Antimicrobial Agents;2008-11

5. β-lactams against emerging ‘superbugs’: progress and pitfalls;Expert Review of Clinical Pharmacology;2008-07